Incyte (NASDAQ:INCY) and Novartis AG (NYSE:NVS) reached a settlement regarding royalty payments in an existing collaboration ...

Incyte said it agreed to pay Novartis $280 million to settle the disputed royalties on U.S. sales of blood-cancer treatment Jakafi through Dec. 31. The parties also agreed to reduce by 50% the royalty ...

We recently published a list of 15 Small-Cap Healthcare Stocks Hedge Funds Are Buying. In this article, we are going to take ...

Shares of Incyte Corp. INCY slid 1.26% to $58.98 Friday, on what proved to be an all-around poor trading session for the ...

Just before the May 5 trial date set for Novartis and Incyte to finally hash out their Jakafi royalty dispute in court, the ...

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Incyte INCY in the ...

The laboratory services company has agreed to purchase certain assets of Incyte's clinical and anatomic pathology testing ...

This week, we take a closer look at two precedential cases concerning pharmaceutical patent protections as applied to drugs in development.

Nanita joined the American Chemical Society Career Consultants program in January 2019, and since then he has provided career ...

Sun Pharmaceutical Industries Ltd. can launch its new hair-loss drug Leqselvi after the Federal Circuit reversed a district ...

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results tomorrow morning. Here’s what investors should know. Incyte beat analysts’ revenue expectations by 3% last ...